{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:36:43Z","timestamp":1790750203409,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>This study sought to assess <jats:sup>18<\/jats:sup>F-fludarabine (<jats:sup>18<\/jats:sup>F-FLUDA) PET\/CT\u2019s ability in differentiating primary central nervous system lymphomas (PCNSLs) from glioblastoma multiformes (GBMs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Patients harboring either PCNSL (n = 8) before any treatment, PCNSL treated using corticosteroids (PCNSLh; n = 10), or GBM (n = 13) were investigated with conventional MRI and PET\/CT, using <jats:sup>11<\/jats:sup>C-MET and <jats:sup>18<\/jats:sup>F-FLUDA. The main parameters measured with each tracer were SUV<jats:sub>T<\/jats:sub> and T\/N ratios for the first 30 minutes of <jats:sup>11<\/jats:sup>C-MET acquisition, as well as at 3 different times after <jats:sup>18<\/jats:sup>F-FLUDA injection. The early <jats:sup>18<\/jats:sup>F-FLUDA uptake within the first minute of injection was equally considered, whereas this parameter was combined with the later uptakes to obtain R FLUDA 2 and R FLUDA 3 ratios.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>No significant differences in <jats:sup>11<\/jats:sup>C-MET uptakes were observed among PCNSL, PCNSLh, and GBM. With <jats:sup>18<\/jats:sup>F-FLUDA, a clear difference in dynamic GBM uptake was observed, which decreased over time after an early maximum, as compared with that of PCNSL, which steadily increased over time, PCNSLh exhibiting intermediate values. The most discriminative parameters consisting of R FLUDA 2 and R FLUDA 3 integrated the early tracer uptake (first 60 seconds), thereby provided 100% specificity and sensitivity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n                                 <jats:sup>18<\/jats:sup>F-FLUDA was shown to likely be a promising radiopharmaceutical for differentiating PCNSL from other malignancies, although a pretreatment with corticosteroids might compromise this differential diagnostic ability. The diagnostic role of <jats:sup>18<\/jats:sup>F-FLUDA should be further investigating, along with its potential of defining therapeutic strategies in patients with PCNSL, while assessing the treatments\u2019 effectiveness.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004238","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T14:03:05Z","timestamp":1651240985000},"page":"699-706","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18F-Fludarabine and l-[methyl-11C]Methionine"],"prefix":"10.1097","volume":"47","author":[{"given":"Andrey","family":"Postnov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Toutain","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, CNRS, ISTCT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Pronin","sequence":"additional","affiliation":[{"name":"N.N. Burdenko National Medical Research Center of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Valable","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, CNRS, ISTCT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Gourand","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, CEA, CNRS, ISTCT\/LDM-TEP group, GIP CYCERON, Caen, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Kalaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Vikhrova","sequence":"additional","affiliation":[{"name":"N.N. Burdenko National Medical Research Center of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pyzhik","sequence":"additional","affiliation":[{"name":"N.N. Burdenko National Medical Research Center of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Guillouet","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, CEA, CNRS, ISTCT\/LDM-TEP group, GIP CYCERON, Caen, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigoriy","family":"Kobyakov","sequence":"additional","affiliation":[{"name":"N.N. Burdenko National Medical Research Center of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Khokholova","sequence":"additional","affiliation":[{"name":"N.N. Burdenko National Medical Research Center of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pitskhelauri","sequence":"additional","affiliation":[{"name":"N.N. Burdenko National Medical Research Center of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Usachev","sequence":"additional","affiliation":[{"name":"N.N. Burdenko National Medical Research Center of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Maryashev","sequence":"additional","affiliation":[{"name":"N.N. Burdenko National Medical Research Center of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Rizhova","sequence":"additional","affiliation":[{"name":"N.N. Burdenko National Medical Research Center of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Potapov","sequence":"additional","affiliation":[{"name":"N.N. Burdenko National Medical Research Center of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Derlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2165\/00003495-200767110-00008","article-title":"Fludarabine: a review of its use in non-Hodgkin\u2019s lymphoma","volume":"67","year":"2007","journal-title":"Drugs"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11307-013-0657-4","article-title":"Fully automated radiosynthesis of 2-F-18 fludarabine for PET imaging of low-grade lymphoma","volume":"16","year":"2014","journal-title":"Mol Imaging Biol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11307-013-0659-2","article-title":"2-F-18 Fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models","volume":"16","year":"2014","journal-title":"Mol Imaging Biol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1021\/acs.molpharmaceut.6b00050","article-title":"Comparative analysis between F-18 Fludarabine-PET and F-18 FDG-PET in a murine model of inflammation","volume":"13","year":"2016","journal-title":"Mol Pharm"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2967\/jnumed.117.206920","article-title":"F-18 fludarabine PET for lymphoma imaging: first-in-humans study on DLBCL and CLL patients","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.7150\/thno.26754","article-title":"F-18 Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: comparative analysis with F-18 FDG in human xenograft models","volume":"8","year":"2018","journal-title":"Theranostics"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s002590000260","article-title":"Non-invasive grading of oligodendrogliomas: correlations between in vivo metabolic pattern and histopathology","volume":"27","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumours of the central nervous system: a summary","volume":"23","year":"2021","journal-title":"Neuro Oncol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.apradiso.2010.07.003","article-title":"Design and performance evaluation of single-use whole-sterile \u201cplug & play\u201d kits for routine automated production of C-11 choline and C-11 methionine with radiopharmaceutical quality","volume":"68","year":"2010","journal-title":"Appl Radiat Isot"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s11307-010-0447-1","article-title":"Comparison of C-11 Methionine PET and F-18 FDG PET in patients with primary central nervous system lymphoma","volume":"13","year":"2011","journal-title":"Mol Imaging Biol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3174\/ajnr.A2171","article-title":"Central nervous system lymphoma: characteristic findings on traditional and advanced imaging","volume":"32","year":"2011","journal-title":"AJNR"},{"key":"bib13-20250621","first-page":"1","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"XX","year":"2021","journal-title":"Neuro Oncol"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"W365","DOI":"10.2214\/AJR.07.2660","article-title":"F-18 FDG PET of common enhancing malignant brain tumors","volume":"190","year":"2008","journal-title":"AJR"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11060-010-0182-0","article-title":"Prognostic value of pretreatment F-18 FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment","volume":"100","year":"2010","journal-title":"J Neurooncol"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12149-011-0483-1","article-title":"Does adding F-18 FDG PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study","volume":"25","year":"2011","journal-title":"Ann Nucl Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00234-012-1089-6","article-title":"Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labelling, diffusion-weighted imaging, and F-18 fluorodeoxyglucose positron emission tomography","volume":"55","year":"2013","journal-title":"Neuroradiology"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"41518","DOI":"10.18632\/oncotarget.17456","article-title":"Diagnostic value of using F-18 FDG PET and PET\/CT in immunocompetent patients with primary central nervous system lymphoma: a systematic review and meta-analysis","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejrad.2018.04.020","article-title":"F-18 FDG PET\/CT in immunocompetent patients with primary central nervous system lymphoma: differentiation from glioblastoma and correlation with DWI","volume":"104","year":"2018","journal-title":"Eur J Radiol"},{"key":"bib20-20250621","first-page":"11","article-title":"Labelling and metabolism of L-[methyl-11C]Methionine","volume":"1","year":"1976","journal-title":"Eur J Nucl Med"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/RLU.0b013e318262af48","article-title":"Differentiation of newly diagnosed glioblastoma multiforme and intracranial diffuse large B-cell lymphoma using C-11 Methionine and F-18 FDG PET","volume":"37","year":"2012","journal-title":"Clin Nucl Med"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1148\/radiographics.14.1.8128041","article-title":"C-11 Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain","volume":"14","year":"1994","journal-title":"Radiographics"},{"key":"bib23-20250621","first-page":"6045894","article-title":"A pilot study of F-18 FLT PET\/CT in pediatric lymphoma","year":"2016","journal-title":"Int J Mol Imaging"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"428","DOI":"10.7150\/thno.13986","article-title":"68Ga-Pentixafor-PET\/CT for imaging of chemokine receptor 4 expression in glioblastoma","volume":"6","year":"2016","journal-title":"Theranostics"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2967\/jnumed.120.241703","article-title":"CXCR4-targeted PET imaging of central nervous system B-cell lymphoma","volume":"61","year":"2020","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:01:28Z","timestamp":1750536088000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004238","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,29]]}}}